A spark of good news for precision oncology in breast cancer
Elaine Schattner writes: Last June, I almost wrote about a drug called AZD5363. It’s an AKT inhibitor, the sort of chemical we studied to see if it killed cancer cells in the lab, years ago. I was intrigued by an ASCO abstract: in an AstraZeneca-sponsored trial of metastatic triple-negative breast cancer this pill significantly extended patients’ overall survival from 12.6 to 19.1 months, vs. placebo, when given with standard paclitaxel chemotherapy.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063